

September 2011

**A. GENERAL INFORMATION**

1. Name **Alexia E. Iasonos PhD**  
 2. Office address: Memorial Sloan-Kettering Cancer Center  
 207 E 63<sup>rd</sup> Street, 3<sup>rd</sup> Floor  
 New York, NY 10065  
 Office telephone: 646-735-8115  
 Office fax: 646-735-0010  
 Email: [iasonosa@mskcc.org](mailto:iasonosa@mskcc.org)

**B. EDUCATIONAL BACKGROUND**

<i>Degree</i>	<i>Institution name and location</i>	<i>Dates</i>	<i>Year Awarded</i>
BS, Mathematics & Statistics	University of Cyprus	9/92-6/96	6/96
MS, Biometry & Statistics	SUNY Albany, Albany, NY	9/96-5/98	6/98
PhD, Biometry & Statistics	SUNY Albany, Albany, NY	8/99-5/02	5/02

**C. PROFESSIONAL POSITIONS AND EMPLOYMENT**Academic positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Assistant Member, Level I	Memorial Sloan-Kettering Cancer Center New York, NY	3/05-4/08
Assistant Member	MSKCC, NY, NY	4/08-

3. Hospital positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Assistant Attending Biostatistician	Memorial Hospital for Cancer & Allied Diseases, New York, NY	3/05-

4. Other Employment

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Teacher Assistant	University at Albany, Albany, NY	9/96-6/97
Research Assistant	NY State Department of Health, Albany, NY	9/97-6/98
Senior Statistician	AC Nielsen, Nicosia, Cyprus	8/98-7/99
Teacher Assistant	University at Albany, Albany, NY	8/99-5/00
Research Assistant	NY State Department of Health, Albany, NY	5/00-11/00
Research Assistant	NY State Department of Labor, Albany, NY	11/00-8/01
Teacher Assistant	University at Albany, Albany, NY	9/01-7/02
Research Biostatistician	Bristol Myers Squibb, Wallingford, CT	8/02-5/05

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure N/A
2. Board Certification N/A
3. Malpractice insurance N/A

E. PROFESSIONAL MEMBERSHIPS

<i>Member/officer</i>	<i>Name of Organization</i>	<i>Dates</i>
Member	American Statistical Association	2001-07
Member	American Society of Clinical Oncology (ASCO)	2006-
Member	Society of Clinical Trials	2009-
Member	International Society of Clinical Biostatistics	2011-

F. HONORS AND AWARDS

<i>Name of award</i>	<i>Date awarded</i>
----------------------	---------------------

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

- Best Presentation Award, Albany Chapter American Statistical Association (ASA) Conference 2001
- Best Paper Award, Albany Chapter ASA Conference 2001
- Pharmaceutical Research Institute Star Award, Bristol Myers Squibb 2003

### G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation: **Memorial Hospital for Cancer and Allied Diseases**  
Other Hospital Affiliations: None  
Other Institutional Affiliations: None

### H. EMPLOYMENT STATUS

Name of Employer(s): Memorial Sloan-Kettering Cancer Center  
Employment Status: Full-time salaried

### I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT

#### 1. Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)

<i>Activity</i>	<i>Dates</i>
<i>MSKCC invited seminars presented:</i>	
Continual Reassessment Method: simulations comparing four methods, Phase I Working Group	2007
A review of Phase I designs in oncology: a comprehensive comparison of the Continual Reassessment Method with the standard 3+3 dose escalation scheme. Biostatistics Forum, Weill Cornell Medical College	2007
Implementation of the continual reassessment method at MSKCC, Phase I Working Group	2008
A comparison of the continual reassessment method with the standard up and down design, MSKCC Experimental Therapeutics Center Retreat	2009
Estimating the dose-toxicity curve from completed Phase I studies, Phase I Working Group	2009

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

Introduction to Biostatistics, Gynecologic Fellows

2010

2. Clinical Care N/A

3. Administrative duties

*Activity*

*Dates*

Data and Safety Monitoring Committee for Phase I & II Trials

3/06-

Junior Faculty Council

10/07-9/09

Phase I Working Group

1/07-

4. Research

My methodological research interest is in the design and analysis of clinical trials, with a focus in Phase I Bayesian adaptive designs. Through my collaborations with the Gynecological Oncology group and the Pathology group, I am exploring various biomarkers and assessing relationships to histology, distant metastasis and clinical outcome. I am heavily involved in vaccine trials as a second line therapy in ovarian cancer patients and identifying valid endpoints for these patients, as part of the Ovarian Program Project. In addition, I am working with surgeons in building predictive models and nomograms in gynecologic cancers.

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	5%	N	Y
Clinical Care	0%	N/A	N/A
Administration	5%	N	Y
Research	90%	N	Y
<b>TOTAL</b>	<b>100%</b>		

### J. RESEARCH SUPPORT

#### Current:

“Early Clinical Trials of New anti-cancer agents with Phase I emphasis”

U01 NIH # CA069856-16

Amount: \$ 258,850

Dates: 4/14/08-2/28/13

PI: David Spriggs

**Role: Co-Investigator, 10% effort**

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

“Designs for phase I trials of combinations of agents”

R01 NIH# CA142859-01A1

Amount: \$ 296,402

Dates: 7/1/11-6/30/13

PI: Mark Conaway

**Role: Subcontract PI, 10% effort**

“Targeting the P13K pathway in women’s cancers”

American Association of Cancer Research, SU2C-AACR-DT0209 (PI Sawyers)

Amount: \$950,000

Dates: 11/1/09-10/31/14

PI: Charles Sawyers

**Role: Co-Investigator, 25% effort**

### Completed:

Assessing the continual reassessment method as a phase I design by comparing it to the standard dose escalation scheme.

Experimental Therapeutic Center at Memorial Sloan Kettering Cancer Center

Amount: \$50,000 (Year 1) , \$70,000 (Year 2)

Dates: 7/1/07-7/1/09

**PI: Alexia Iasonos PhD**

**Role: PI, 40% effort**

The Byrne Foundation

Amount: \$320,000

Dates: 1/1/06-12/31/07

PI: George Bosl

**Role: Co-Investigator, 20% effort**

“Novel Approaches to Ovarian Cancer Treatment”

P20 OCRF-CA-01

Amount: \$225,000

Dates: 12/31/04-12/30/07

PI: Carol Aghajanian

**Role: Co-Investigator, 15% effort**

“Epithelial Ovarian Cancer Program Project”

PO1 NIH # CA 52477-13A3

Amount: \$1,111,409

Dates: 4/1/05-3/31/10

PI: David Spriggs

**Role: Core Co-PI, 40% effort**

PO1 CA05826-38, NIH/ NCI

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

Amount: \$203,888

Dates: 12/1/02 –11/30/05

PI: George Bosl; Biostat Core PI: Colin Begg

**Role: Investigator**, 10% effort

### K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

#### International Activities:

International Workshop in the Statistical Design of Phase I Studies, Organizer & Chair, 2009

#### National & Regional Activities:

American Statistical Association, Education Committee Chair, Connecticut Chapter, 2003-05

American Statistical Association, Treasurer (elected), Connecticut Chapter, 2004-05

Susan G. Komen for the Cure, Scientific Reviewer, 2008-

Caucus for Women in Statistics, Representative (elected), 2008-09

ASCO Program Committee, Biostatistics Track, Reviewer, 2009-

Special Issue in Statistics in Medicine in Phase I Design, Guest Editor, 2010

#### Invited Seminars Presented:

Albany Chapter American Statistical Association Meeting, NY, 2001

Albany Chapter American Statistical Association Meeting, NY, 2002

Weill Cornell Medical College, Biostatistics Seminar, NY, 2007

University of Pennsylvania, Biostatistics Seminar, Philadelphia, PA, 2009

Baruch College, City University of New York, Biostatistics Seminar, New York, NY, 2009

University of Reading, Workshop on dose-finding methodology in early phase clinical trials, UK, 2010

University of California San Francisco, Biostatistics Seminar, CA, 2011

Universite Paris 6, Second workshop on dose-finding methodology in early phase clinical trials, France, 2011.

Journal review:

Journal of Clinical Oncology

Clinical Trials

Statistics in Medicine

Biometrics

Controlled Clinical Trials

**L. BIBLIOGRAPHY**1. Peer-Reviewed Articles

1. Raj GV, **Iasonos A**, Herr H, Donat MS, Formulas Calculating Creatinine Clearance Are Inadequate For Determining Eligibility For Cisplatin-Based Chemotherapy In Bladder Cancer. J Clin Oncol 2006; 24:3095-100.
2. Abu-Rustum N, Alektiar K, **Iasonos A**, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The Incidence of Symptomatic Lower-Extremity Lymphedema Following Treatment of Uterine Corpus Malignancies: An 11-Year Experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006;103(2):714-8.
3. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, **Iasonos A**, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I Study of the Anti-Idiotypic Monoclonal Antibody Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clin Cancer Res 2006; 12:5503-10.
4. Juretzka MM, Barakat RR, Chi DS, **Iasonos A**, et al. CA125 Level as a Predictor of Progression Free Survival and Overall Survival in Ovarian Cancer Patients with Surgically Defined Disease Status at the End of Primary Therapy. Gynecol Oncol 2007; 104:176-80
5. Raj GV, Bach AM, **Iasonos A**, Korets R, Blitstein J, Hann L, Russo P Predictng the histology of renal masses using pre-operative doppler ultrasonography. Journal of Urology 2007; 177:53-8.
6. Diefenbach CSM., Soslow RA, **Iasonos A**, Hedvat C, Bonham L, Singer J, Barakat R., Aghajanian C., Dupont J. Lysophosphatidic Acid Transferase-Beta (LPAAT-β) is Highly Expressed in Advanced Ovarian Cancer and is Associated with Aggressive Histology, Distant Metastases and Poor Survival. Cancer 2006; 107:1511-9
7. Diefenbach CSM, Shah Z, **Iasonos A**, Barakat RR et al. Pre-operative serum YKL-40 is a serum marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007; 104:435-42

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

8. Sabbatini P, Mooney D, **Iasonos A**, Thaler H, Aghajanian C, Hensley M, Tew W, Konner J, Spriggs D, Abu-Rustum N, Dupont J. CA-125 Patterns in Recurrent Ovarian Cancer treated with Carboplatin, Liposomal Doxorubicin, or Topotecan. *Int J Gynecol Cancer* 2007; 17:589-94
9. Basch E, **Iasonos A**; McDonough T, Barz A; Culkin A RN; Kris M; Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). *The Lancet Oncology* 2006; 7:903-9
10. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. *Cancer* 2007; 109:549-55
11. Galsky MD, Mironov S, **Iasonos A**, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. *Invest New Drugs* 2007; 25:265-70
12. Basch E, Artz D, Speakman J, **Iasonos A**, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. *J Am Med Inform Assoc* 2007; 14:264-8
13. Dos Santos L, Mok E, **Iasonos A**, Park K, Soslow RA, Aghajanian C, Alektiar K, Barakat RR, Abu-Rustum NR. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature. *Gynecol Oncol* 2007; 105:321-4
14. Sabbatini P, Ragupathi G, Hood C, Aghajanian C, Juretzka M, **Iasonos A**, Hensley M, Spriggs D, Tew W, Konner J, Clausen H, Rustum NA, Dansie H, Livingston P. Pilot study of a heptavalent vaccine-KLH conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. *Clin Cancer Res* 2007; 13:4170-7
15. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. *Urology* 2007; 69:255-9.
16. Harrison ML, Gore ME, Spriggs D, Kaye S, **Iasonos A**, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. *Gynecol Oncol* 2007; 106:469-75.
17. Black D, **Iasonos A**, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. *Gynecol Oncol* 2007; 107:66-70.
18. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, **Iasonos A**, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. *Cancer* 2007; 110:2458-66.

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

19. Basch E, **Iasonos A**, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. *J Clin Oncol* 2007 Dec 1;25(34):5374-80.
20. Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, **Iasonos A**, Soslow R, Park K, Sabbatini P. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. *Eur J Gynaecol Oncol*. 2008;29(6):568-72.
21. **Iasonos A**, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. *Clin Trials*. 2008;5(5):465-77. PMID: PMC2637378.
22. Zivanovic O, Eisenhauer EL, Zhou Q, **Iasonos A**, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol*. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.
23. Caceres A, Zhou Q, **Iasonos A**, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. *Gynecol Oncol*. 2008 Mar;108(3):482-5. Epub 2008 Jan 10.
24. **Iasonos A**, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008 Mar 10;26(8):1364-70. Review.
25. Black D, Levine DA, Nicoll L, Chou JF, **Iasonos A**, Brown CL, Sonoda Y, Chi DS, Leitao MM, Abu-Rustum NR, Ferguson SE, Barakat RR. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. *Gynecol Oncol*. 2008 Apr;109(1):39-42. Epub 2008 Jan 29.
26. Abu-Rustum NR, **Iasonos A**, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? *Am J Obstet Gynecol*. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6.
27. Diefenbach CS, Gnjjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, **Iasonos A**, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. *Clin Cancer Res*. 2008 May 1;14(9):2740-8.
28. Thompson RH, Ordonez MA, **Iasonos A**, Secin FP, Guillonneau B, Russo P, Touijer K. Renal cell carcinoma in young and old patients--is there a difference? *J Urol*. 2008 Oct;180(4):1262-6; discussion 1266. Epub 2008 Aug 15. PMID: PMC2615196.
29. Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, **Iasonos A**, Hensley ML. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. *Gynecol Oncol*. 2008 Nov;111(2):249-54. Epub 2008 Aug 27.

## CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

30. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, **Iasonos A**, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. *Gynecol Oncol*. 2008 Nov;111(2):265-70. Epub 2008 Sep 6.
31. Zivanovic O, Leitao MM, **Iasonos A**, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. *J Clin Oncol*. 2009 Apr 20;27(12):2066-72. Epub 2009 Mar 2.
32. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, **Iasonos A**, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. *J Clin Oncol*. 2009 Sep 1;27(25):4062-7. Epub 2009 Jul 27.
33. Zivanovic O, Sima CS, **Iasonos A**, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. *Gynecol Oncol*. 2009 Nov;115(2):209-14. Epub 2009 Aug 7. PubMed
34. Gallagher DJ, Milowsky MI, **Iasonos A**, Maluf FC, Russo P, Dalbagni G, Donat MS, Boyle MG, Zheng J, Riches J, Bajorin DF. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. *Cancer*. 2009 Nov 15;115(22):5193-201.
35. O'Cearbhaill R, Zhou Q, **Iasonos A**, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. *Gynecol Oncol*. 2009 Nov 23. [Epub ahead of print]
36. O'Cearbhaill R, Zhou Q, **Iasonos A**, Hensley ML, Tew WP, Aghajanian C, Spriggs DR, Lichtman SM, Sabbatini PJ. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. *Gynecol Oncol*. 2009 Nov 25. [Epub ahead of print]
37. Garg K, Shih K, Barakat R, Zhou Q, **Iasonos A**, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. *Am J Surg Pathol*. 2009 Dec;33(12):1869-77.
38. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, **Iasonos A**, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. *J Natl Cancer Inst*. 2009 Dec 2;101(23):1624-32. Epub 2009 Nov 17. PMID: PMC2786917.

## CURRICULUM VITAE

## ALEXIA E. IASONOS, Ph.D.

39. Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, **Iasonos A**. Consolidation strategies in ovarian cancer: observations for future clinical trials. *Gynecol Oncol*. 2010 Jan;116(1):66-71.
40. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, **Iasonos A**. A Nomogram for Predicting Overall Survival of Women with Endometrial Cancer Following Primary Therapy: Toward Improving Individualized Cancer Care *Gynecol Oncol*. 2010 Mar;116(3):399-403.
41. Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, **Iasonos A**, Brown CL, Abu-Rustum NR. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. *Gynecol Oncol*. 2010 Nov;119(2):358-65. PubMed PMID: 20817227.
42. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, **Iasonos A**, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. *Gynecol Oncol*. 2010 Nov;119(2):270-3. Epub 2010 Aug 16. PubMed PMID: 20719369.
43. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, **Iasonos A**, Goodglick L, Gordon LK, Braun J, Wadehra M. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. *Clin Cancer Res*. 2010 Aug 1;16(15):3954-63. PubMed PMID: 20670949; PubMed Central PMCID: PMC2913478.
44. Dharma Rao T, Park KJ, Smith-Jones P, **Iasonos A**, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. *Appl Immunohistochem Mol Morphol*. 2010 Oct;18(5):462-72. PubMed PMID: 20453816.
45. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, **Iasonos A**, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. *J Clin Oncol*. 2010 Apr 10;28(11):1896-903. Epub 2010 Mar 8. PubMed PMID: 20212248.
46. Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. *Gynecol Oncol*. 2010 May;117(2):317-23. Epub 2010 Feb 16. PubMed PMID: 20163847.
47. Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. *Gynecol Oncol*. 2010 Mar;116(3):351-7. PubMed PMID: 20022092.
48. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. *Gynecol Oncol*. 2010 Dec 9. [Epub ahead of print] PubMed PMID: 21146201.

49. **Iasonos A.**, Ostrovnya I. Estimating the dose-toxicity curve in completed phase I studies. *Statistics in Medicine* 2011 Jul 30;30(17):2117-29.
50. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, **Iasonos A**, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. *Clin Cancer Res.* 2011 Apr 15;17(8):2493-501. Epub 2011 Feb 23.
51. Abu-Rustum NR, Zhou Q, **Iasonos A**, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? *Int J Gynecol Cancer.* 2011 Apr;21(3):511-6
52. Zivanovic O, Jacks LM, **Iasonos A**, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. *Cancer.* 2011 Jul 12. doi: 10.1002/cncr.26333.
53. **Iasonos A**, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. *Clin Trials.* 2011;8(4):370-9.
54. Hyman DM, Zhou Q, Arnold AG, Grisham RN, **Iasonos A**, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. *Gynecol Oncol.* 2011 Aug 18. [Epub ahead of print]
55. Hensley ML, Kravetz S, Jia X, **Iasonos A**, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. *Cancer.* 2011 Sep 20. doi: 10.1002/cncr.26569. [Epub ahead of print]
56. **Iasonos A**, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Identifying Clinical Improvement in Consolidation Single-arm Phase II Trials in Ovarian Cancer Patients in Second or Greater Clinical. *International Journal of Gynecological Cancer* 2011 (in press).

## 2. Books, book chapters and reviews

1. **Iasonos A.** Statistics for the beginners in gynaecologic oncology. *Textbook of Gynaecological Oncology*, ESGO-ENYGO Endorsed. Gunes Tip Kitabevleri, 2009, p. 150.
2. **Iasonos A.**, O'Quigley J. Continual reassessment and related designs in dose finding studies. *Statistics in Medicine.* 2011 Jul 30;30(17):2057-61. Editorial.
3. O'Quigley J, **Iasonos A.** Dose finding designs based on the continual reassessment method. *Handbook of Statistics in Clinical Oncology* ed. by John Crowley and Marcel Dekker. 2011

3. Abstracts

1. Abu-Rustum NR, Alektiar K, Lev G, **Iasonos A**, Sonoda Y, Aghajanian C, Barakat RR, ChiDS. The incidence of symptomatic lower extremity lymphedema following treatment of uterine corpus malignancies: An 11 year experience at Memorial Sloan-Kettering Cancer Center. Presented at the 2005 Society Gynecologic Oncology.
2. Persky D, Portlock CS, Lessac-Chenen S, **Iasonos A**, Zelenetz AD, Kewalramani T, Rice D, Yahalom J, Nimer SD, Moskowitz CH. The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL). Presented at the 2005 American Society Hematology.
3. Persky D, Teruya-Feldstein J, Kewalramani T, Bonner PD, **Iasonos A**, Rice D, Yahalom J, Nimer SD, Zelenetz AD, Moskowitz CH. High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma. Presented at the 2005 American Society Hematology.
4. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Donat SM, Bochner Bochner BH, Her HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell (non-TCC) carcinomas of the urothelial tract. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4542
5. Basch EM, McDonough T, **Iasonos A**, Siegel E, Culkin A, Kris M, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 8515
6. Raj GV, **Iasonos A**, Bach A, Hann L, Russo P. Predicting the histology of renal masses using pre-operative Doppler ultrasonography. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4598.
7. Basch EM, Barz A, **Iasonos A**, Culkin A, Kris M, Speakman J, Artz D, Schrag D. Online reporting of toxicity symptoms by lung cancer patients during chemotherapy. Presented at the 2006 annual U.S. meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, PA.
8. Basch EM, **Iasonos A**, McDonough T, Barz A, Culkin A, Kris M, Scher HI, Schrag D. Patient and clinician symptom reporting using the CTCAE. Presented at the 2006 meeting, National Cancer Institute Patient Reported Outcomes Assessment in Cancer Trials (NCI PROACT), Bethesda, MD.
9. Basch EM, **Iasonos A**, Barz A, Culkin A, Kris M, Scher HI, Schrag D. Online symptom reporting by cancer patients. Presented at the 2006 11<sup>th</sup> World Congress on Internet in Medicine (Mednet), Toronto, Canada.

## CURRICULUM VITAE

**ALEXIA E. IASONOS, Ph.D.**

10. Abu-Rustum NR, Alektiar K, **Iasonos A**, Lev G, Sonoda Y, Aghajanian, Chi DS, Barakat RR. Surgical Removal of Pelvic Lymph Nodes Influences Endometrial Cancer Outcomes: An 11-Year Study. 2006 International Gynecologic Cancer Society Meeting, IGCS
11. Moss RA, Phillips MK, **Iasonos A**, Konner J. "CA125 Nadir and Religious Preference as Prognostic Markers in Ovarian Cancer". Presented at the Lynne Cohen Foundation for Ovarian Cancer Research Conference on The Emerging Role of Screening and Prevention in Women's Cancer, New York University, New York, NY, May 4-5, 2006
12. Ordonez M, Snyder M, **Iasonos A**, Secin F, Russo P, Guillonneau B, Touijer K. Analysis of clinical-pathological features and survival for patients under the age of 40 with renal cortical tumours. European Urology Supplements, Volume 5, Issue 2, April 2006, Page 107
13. Touijer K, **Iasonos A**, Mitra N, Cho E, Bochner B, Herr H, Dalbagni G, and Donat SM. Does Body Mass Index (BMI) Affect the Quality and Morbidity of Radical Cystectomy for Bladder Cancer? Accepted for podium session AUA, San Antonio, TX, May 2005.
14. Black D, **Iasonos A**, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Venous thromboembolism and survival in ovarian, primary peritoneal and fallopian tube cancer patients. Presented at the 2006 Society Gynecologic Oncology.
15. Lewin SN, Magid CS, Soslow RA, **Iasonos A**, Linkov I, Barakat RR, Aghajanian CA, Dupont J. High AKT expression in epithelial ovarian cancer (EOC) correlates with poor clinical outcome which is not ameliorated by PTEN. Presented at the 2006 Society Gynecologic Oncology.
16. Lewin SN, **Iasonos A**, Tracy B, Hansen J, Kosarin K, Chou JF, Castiel M, Barakat RR, Offit K, Kauff ND. The Impact of Hormone Replacement Therapy on Post-Menopausal Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Presented at the 2006 Society Gynecologic Oncology.
17. Bajorin DF, Ostrovnaya I, **Iasonos A**, Milowsky M. I., Boyle M, Riches J. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5055
18. **Iasonos A**, Schrag D, Raj GV, Russo P, Panageas KS. Uncertainty around individualized predictions using nomograms: The concept of individualized prediction intervals. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6526
19. Konner JA, Fallon K, Pezzuli S, **Iasonos A**, Sabbatini P, Hensley M, Chiang A, Tew W, Spriggs D, Aghajanian C. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5523
20. Basch EM, **Iasonos A**, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Scher HI, Schrag D. Long-term toxicity monitoring via electronic patient reported outcomes in end-stage chemotherapy

## CURRICULUM VITAE

## ALEXIA E. IASONOS, Ph.D.

- patients. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June Supplement), 2007: 9025
21. Gallagher DJ, Milowsky MI, Gerst SR, **Iasonos A**, Riches J, Boyle MG, Bajorin DF. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5080
  22. Abu-Rustum NR, **Iasonos A**, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic benefit to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?" Presented as an invited paper at the 2007 American Gynecological and Obstetrical Society
  23. Zivanovic O, Eisenhauer EL, Zhou Q, **Iasonos A**, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Barakat RR, Chi DS. A Cytoreductive outcomes in patients with stage IIIC epithelial ovarian, fallopian tube or primary peritoneal cancer and moderate to large volume ascites, SGO 2007 (San Diego, California, April 2007).
  24. Zivanovic O, **Iasonos A**, Leitao MM, Zhou Q, Soslow RA, Juretzka MM, Chi DS, Brennan MF, Hensley ML. Stage-Specific Survival of Patients with Uterine Leiomyosarcoma: A Comparison of FIGO and AJCC Staging System, ASCO 2008 (Chicago, Illinois, May 2008) *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 5554)
  25. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, **Iasonos A**, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment Patterns of FIGO Stage IB2 Cervical Cancer: Radical Hysterectomy with Individualized Postoperative Therapy or Definitive Radiation Therapy with or without Chemotherapy, oral presentation at SGO Winter Meeting 2008 (Park City, Utah, February 2008)
  26. Zivanovic O, **Iasonos A**, Leitao MM, Zhou Q, Soslow RA, Juretzka MM, Chi DS, Brennan MF, Hensley ML. Stage-Specific Survival of Patients with Uterine Leiomyosarcoma: A Comparison of FIGO and AJCC Staging System, plenary presentation at the 14<sup>th</sup> Annual Meeting of the Connective Tissue Oncology Society (November 2008, London, UK)
  27. Zivanovic O, Sima CS, **Iasonos A**, Martinez AR, Pingle PR, Leitao MM, Sonoda Y, Abu-Rustum NR, Eisenhauer EL, Barakat RR, Chi DS. Upper Abdominal Disease Cephalad to the Greater Omentum and the Impact on Progression-Free Survival in Patients with Stage IIIC Ovarian Cancer, opening plenary presentation at SGO 2009 (San Antonio, Texas, February 2009)
  28. **Iasonos A**, Riedel ER, Spriggs DR. Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme? ASCO 2008. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 2559)
  29. Gallagher DJ, Milowsky MI, Gerst SR, **Iasonos A**, Boyle MG, Trout A, Riches J, Bajorin DF. Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. 2008 ASCO. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 5082)
  30. **Iasonos A**, Riedel E. Is the Continual Reassessment Method a better Phase I Design? A comprehensive comparison with the standard 3+3 dose escalation scheme. ENAR, International Biometric Society 2008.

31. Abu-Rustum NR, Zhou Q, **Iasonos A**, Soslow R, Sabbatini P, Levine D, Alektiar K, Chi DS, Barakat RR. Does Clear Cell Endometrial Carcinoma Have a Similar Prognosis to Serous Endometrial Carcinoma? SGO 2008.
32. Spriggs DR, **Iasonos A.**, Sabbatini P., O'Cearbhaill R. E., Thaler H. T. Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 5032).
33. **Iasonos A.**, Zohar S., O'Quigley J. Two-stage continual reassessment method that determines dose-escalation based on individual toxicity grades. Society of Clinical Trials 31<sup>st</sup> Annual Meeting 2010 (abstract P94).
34. **Iasonos A.** O'Quigley J. The impact of priors and skeletons in model based dose finding studies. 32<sup>nd</sup> Annual Meeting of International Society of Clinical Biostatistics. 2011.

4. Poster or Contributed Oral Presentations:

1. **Iasonos A**, Zurbenko IG. An Evaluation Model for the Performance of a Company Relative to the Market. Proceedings of the Joint Statistical Meeting, 2001.
2. **Iasonos A**, Zurbenko I.G. The effect of missing data on linear filters. Proceedings of the Joint Statistical Meeting 2002.
3. **Iasonos A**, Chen T., Maniero A., Bogaerts J. QoL in Oncology: A Review of Several Models for the Area Under the Curve Analysis. Proceedings of the Joint Statistical Meeting 2003.
4. **Iasonos A.** Raj GV. Utility of pre-operative doppler ultrasonography in predicting histology of renal masses. Joint Statistical Meeting 2006.
5. **Iasonos A**, Schrag D, Raj GV, Russo P, Panageas KS. Uncertainty around individualized predictions using nomograms: The concept of individualized prediction intervals. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6526.
6. **Iasonos A**, Wilton AS.; Riedel ER.; Seshan V. Is the Continual Reassessment Method a better Phase I design? A comprehensive comparison with the standard 3+3 dose escalation scheme. International Biometrics Society, ENAR 2008 Meeting.
7. **Iasonos A**, Riedel ER, Spriggs DR . Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme? ASCO 2008. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 2559).
8. **Iasonos A.**, Zohar S., O'Quigley J. Two-stage continual reassessment method that determines dose-escalation based on individual toxicity grades. Society of Clinical Trials 31<sup>st</sup> Annual Meeting 2010 (abstract P94).

## CURRICULUM VITAE

**ALEXIA E. IASONOS, Ph.D.**

9. Spriggs DR, **Iasonos A.**, Sabbatini P., O'Cearbhaill R. E., Thaler H. T. Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 5032).
10. **Iasonos A.** O'Quigley J. The impact of priors and skeletons in model based dose finding studies. 32<sup>nd</sup> Annual Meeting of International Society of Clinical Biostatistics. 2011.